These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24323472)

  • 21. Current perspectives on echinocandin class drugs.
    Perlin DS
    Future Microbiol; 2011 Apr; 6(4):441-57. PubMed ID: 21526945
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Monitoring Antifungal Resistance in a Global Collection of Invasive Yeasts and Molds: Application of CLSI Epidemiological Cutoff Values and Whole-Genome Sequencing Analysis for Detection of Azole Resistance in Candida albicans.
    Castanheira M; Deshpande LM; Davis AP; Rhomberg PR; Pfaller MA
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28784671
    [TBL] [Abstract][Full Text] [Related]  

  • 23. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872).
    Bartizal K; Gill CJ; Abruzzo GK; Flattery AM; Kong L; Scott PM; Smith JG; Leighton CE; Bouffard A; Dropinski JF; Balkovec J
    Antimicrob Agents Chemother; 1997 Nov; 41(11):2326-32. PubMed ID: 9371328
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rate of FKS Mutations among Consecutive Candida Isolates Causing Bloodstream Infection.
    Shields RK; Nguyen MH; Press EG; Cumbie R; Driscoll E; Pasculle AW; Clancy CJ
    Antimicrob Agents Chemother; 2015 Dec; 59(12):7465-70. PubMed ID: 26392494
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Echinocandin and triazole antifungal susceptibility profiles for Candida spp., Cryptococcus neoformans, and Aspergillus fumigatus: application of new CLSI clinical breakpoints and epidemiologic cutoff values to characterize resistance in the SENTRY Antimicrobial Surveillance Program (2009).
    Pfaller MA; Castanheira M; Messer SA; Moet GJ; Jones RN
    Diagn Microbiol Infect Dis; 2011 Jan; 69(1):45-50. PubMed ID: 21146713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ibrexafungerp: A novel oral glucan synthase inhibitor.
    Davis MR; Donnelley MA; Thompson GR
    Med Mycol; 2020 Jul; 58(5):579-592. PubMed ID: 31342066
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Use of fluorescent probes to determine MICs of amphotericin B and caspofungin against Candida spp. and Aspergillus spp.
    Peter J; Armstrong D; Lyman CA; Walsh TJ
    J Clin Microbiol; 2005 Aug; 43(8):3788-92. PubMed ID: 16081911
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
    Marcos-Zambrano LJ; Gómez-Perosanz M; Escribano P; Zaragoza O; Bouza E; Guinea J
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Antifungal activities of SCY-078 (MK-3118) and standard antifungal agents against clinical non-Aspergillus mold isolates.
    Lamoth F; Alexander BD
    Antimicrob Agents Chemother; 2015 Jul; 59(7):4308-11. PubMed ID: 25896696
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations.
    Alexander BD; Johnson MD; Pfeiffer CD; Jiménez-Ortigosa C; Catania J; Booker R; Castanheira M; Messer SA; Perlin DS; Pfaller MA
    Clin Infect Dis; 2013 Jun; 56(12):1724-32. PubMed ID: 23487382
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical perspectives on echinocandin resistance among Candida species.
    Shields RK; Nguyen MH; Clancy CJ
    Curr Opin Infect Dis; 2015 Dec; 28(6):514-22. PubMed ID: 26524326
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Stress-Induced Changes in the Lipid Microenvironment of β-(1,3)-d-Glucan Synthase Cause Clinically Important Echinocandin Resistance in Aspergillus fumigatus.
    Satish S; Jiménez-Ortigosa C; Zhao Y; Lee MH; Dolgov E; Krüger T; Park S; Denning DW; Kniemeyer O; Brakhage AA; Perlin DS
    mBio; 2019 Jun; 10(3):. PubMed ID: 31164462
    [No Abstract]   [Full Text] [Related]  

  • 33. In vitro activities of anidulafungin and other antifungal agents against biofilms formed by clinical isolates of different Candida and Aspergillus species.
    Fiori B; Posteraro B; Torelli R; Tumbarello M; Perlin DS; Fadda G; Sanguinetti M
    Antimicrob Agents Chemother; 2011 Jun; 55(6):3031-5. PubMed ID: 21422210
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Potency of anidulafungin compared to nine other antifungal agents tested against Candida spp., Cryptococcus spp., and Aspergillus spp.: results from the global SENTRY Antimicrobial Surveillance Program (2008).
    Messer SA; Jones RN; Moet GJ; Kirby JT; Castanheira M
    J Clin Microbiol; 2010 Aug; 48(8):2984-7. PubMed ID: 20534798
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CD101, a long-acting echinocandin, and comparator antifungal agents tested against a global collection of invasive fungal isolates in the SENTRY 2015 Antifungal Surveillance Program.
    Pfaller MA; Messer SA; Rhomberg PR; Castanheira M
    Int J Antimicrob Agents; 2017 Sep; 50(3):352-358. PubMed ID: 28689871
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Caspofungin: when and how? The microbiologist's view.
    Mayr A; Aigner M; Lass-Flörl C
    Mycoses; 2012 Jan; 55(1):27-35. PubMed ID: 21668518
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antifungal activity of micafungin against Candida and Aspergillus spp. isolated from pediatric patients in Japan.
    Ikeda F; Saika T; Sato Y; Suzuki M; Hasegawa M; Mikawa T; Kobayashi I; Tsuji A
    Med Mycol; 2009 Mar; 47(2):145-8. PubMed ID: 18668422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Echinocandin antifungal drugs in fungal infections: a comparison.
    Chen SC; Slavin MA; Sorrell TC
    Drugs; 2011 Jan; 71(1):11-41. PubMed ID: 21175238
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Aldejohann AM; Menner C; Thielemann N; Martin R; Walther G; Kurzai O
    Antimicrob Agents Chemother; 2024 Feb; 68(2):e0132423. PubMed ID: 38206004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical breakpoints for the echinocandins and Candida revisited: integration of molecular, clinical, and microbiological data to arrive at species-specific interpretive criteria.
    Pfaller MA; Diekema DJ; Andes D; Arendrup MC; Brown SD; Lockhart SR; Motyl M; Perlin DS;
    Drug Resist Updat; 2011 Jun; 14(3):164-76. PubMed ID: 21353623
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.